Olwen Hahn, MD, specializes in the diagnosis and treatment of breast cancer. Dr. Hahn’s practice primarily focuses on treating patients with all forms of breast cancer. For a comprehensive range of breast cancer treatments, Dr. Hahn offers both standard of care, such as chemotherapy, targeted therapy and endocrine therapy, as well as therapeutic clinical trials in order to deliver the best care for her patients. She is also a proponent of using systemic therapy (chemotherapy, targeted therapy, immunotherapy or endocrine therapy) prior to surgery (neoadjuvant therapy) to better understand how each patient’s individual tumor responds to therapy.
In addition to her clinical practice, Dr. Hahn is committed to elevating cancer care through clinical trials, and is a strong advocate in offering clinical trials to her patients. Additionally, she has worked with the National Cancer Institute (NCI)-sponsored cooperative group Cancer and Leukemia Group B (CALGB) and the Alliance for Clinical Trials in Oncology as an Executive Officer between 2008-2017, where she assisted in the development and conduct of oncology clinical trials. In 2019, she assumed the position of Director and Principal Investigator of the Alliance Central Protocol Operations Program. In this role, Dr. Hahn oversees the clinical operations for a large portfolio of multi-institutional, national oncology studies.